Article

Death risk is low if prostate cancer hasn't progressed in 10 years

Most biochemical recurrence of prostate cancer following radical prostatectomy occurs within 10 years, and patients who remain free from progression a decade postoperatively can be counseled that their risk of subsequent cancer-related morbidity and mortality is low.

Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Closeup of patient with prescription | Image Credit: © gpointstudio - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Landon Trost, MD, answers a question during a Zoom video interview
Related Content
NeuroSAFE procedure for RARP leads to improved erectile function
March 27th 2025

NeuroSAFE procedure for RARP leads to improved erectile function

Hannah Clarke
“Our results show that by using NeuroSAFE, nearly twice as many men don’t have to face potentially life-changing loss of erectile function after prostate surgery,” says Professor Greg L. Shaw.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
RAG-01 elicits complete responses in NMIBC
March 26th 2025

RAG-01 elicits complete responses in NMIBC

Hannah Clarke
"The striking CR rates observed in these early cohorts are highly encouraging, particularly for BCG-unresponsive NMIBC patients who currently have limited treatment options," says Paul D. Anderson, MBBS, FRACS.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Bel-sar shows promising safety, efficacy in NMIBC
March 26th 2025

Bel-sar shows promising safety, efficacy in NMIBC

Hannah Clarke
In patients with intermediate-risk disease, 4 of 5 patients demonstrated a complete response.
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL
"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.
© 2025 MJH Life Sciences

All rights reserved.